19 May - 20 May 2014

Kinase 2014: past, present and beyond

Organised by:

SCI's Fine Chemicals Group and RSC's Biological & Medicinal Chemistry Sector

Babraham Research Campus, Cambridge, UK

Registration Closed

This event is no longer available for registration.

Synopsis

Now with over twenty FDA-approved small molecules, the field of kinase inhibition has matured. The sixth RSC/SCI symposium on kinases will encompass case studies of on-going programmes as well as successful past kinase programmes, with examples from the CNS, inflammation/respiratory and oncology fields being presented. The question of emerging resistance to kinase inhibitors will be raised along with techniques being developed to address this. The symposium will also include views, perspectives and discussions on the future of kinase inhibitor research.

Attendees

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

Programme

Day 1 - Monday 19 May

09:00: Registration
10:00: Opening Remarks
10:10: Clinical experience with kinase inhibitors for the treatment of cancer
Andrew Mortlock, AstraZeneca, UK
10:50: The discovery and optimisation of a series of potent, selective and CNS restricted pan-Trk ligands for pain
Sharan Bagal, Pfizer Neusentis, UK
11:30: Chemoproteomic applications in kinase drug discovery
Douglas Thomson, Cellzome, Germany
12:10: Lunch
13:10: Fragment-based discovery of selective inhibitors of maternal embryonic leucine zipper kinase
Chris Johnson, Astex Pharmaceuticals, UK
13:50: Brain penetrant PI3K inhibitors for the treatment of glioblastoma: optimisation of free brain concentrations using an MPO approach
Robert Heald, Argenta, UK
14:30: Inhalation by design: the discovery of slow-offset Janus Kinase (JAK) inhibitors towards the treatment of respiratory diseases
Ian Storer, Pfizer, UK
15:10: Refreshments
15:40: Non-ATP site-directed kinase inhibitors
Andreas Marzinzik, Novartis, Switzerland
16:20: Introduction to the RSC / CPA (Royal Society of Chemistry / Chinese Pharmaceutical Association) session at Kinase 2014
Kathleen Too, Royal Society of Chemistry
16:25: Discovery and preclinical evaluation of HMPL-504 (AZD6094/Volitinib): a potent, selective and orally active c-Met kinase inhibitor for cancer
Weiguo Su, Hutchinson MediPharma
16:45: New kinase inhibitors targeting the clinically acquired resistant mutants
Ke Ding, Institute of Biomedicine and Health, Guangzhou
17:05: Lucitanib: a dual-kinase inhibitor targeting FGFR and VEGFR
Min Huang, Shanghai Institute of Materia Medica
17:25: Drinks reception and poster session followed by conference barbecue
19:15: Barbecue ends

Day 2 - Tuesday 20 May

Section 1

09:00: Acquired resistance to kinase inhibitors - the problem and some solutions
Simon Cook, The Babraham Institute, UK
09:40: The resurgence of covalent drugs
Russell Petter, Celgene, USA
10:20: Refreshments
10:50: The discovery of AZD9291: a mutant selective, third generation EGFR inhibitor
Ray Finlay, AstraZeneca, UK
11:30: Discovery and characterisation of potent and selective inhibitors of ATR kinase as anti-cancer agents
John Pollard, Vertex Pharmaceuticals, UK
12:10: Lunch
13:!0: LY2835219. A CDK4/6 dual inhibitor with unique pharmacology and physicochemical properties
Concepcion Sanchez-Martinez, Lilly, Spain
13:50: Interactive session
14:30: Targeting oncogenic kinases and K-RAS with covalent inhibitors
Nathaneal Gray, Harvard, USA
15:10: Closing Remarks

Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

Venue and Contact

Babraham Research Campus

Cambridge, UK

Maggi Churchouse

Tel: +44 (0)1359 221004

Email: maggi@maggichurchouseevents.co.uk

Fees

Earlybird fees - before 31 March 2014
GB£240 . . . . . . . . .SCI / RSC Member
GB£290 . . . . . . . . .Non Member

Standard fees - from 1 April 2014
GB£280 . . . . . . . . .SCI / RSC Member
GB£330 . . . . . . . . .Non Member
GB£125 . . . . . . . . .SCI / RSC Student Member - flat rate
GB£150 . . . . . . . . .Student Non Member - flat rate

Become an SCI Member and save on this and future events

See Membership Options

Booking Process/Deadlines

Booking terms and conditions

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Additional Info

Organising committee

Jackie Macritchie, BioFocus and RSC
Roger Griffin, Newcastle University
John Harris, CJH Consultants
Keith Jones, Institute of Cancer Research and SCI
Sarah Rook, Evotec and SCI
Andrew Thomas, AstraZeneca
Kevin Doyle, BioFocus

Call for Papers

A poster session will take place at the end of Day 1. A one-page abstract should be submitted to the Secretariat by 31st March 2014. When submitting posters, delegates should indicate whether they would be prepared to give a single-slide summary of their poster in a formal presentation session that will take place on Day 1.

Sponsorship and Exhibition

The exhibition is now full, although interested companies may wish to book a delegate pack insert via the Secretariat. Sponsors are encouraged to support this established event.

Students and Bursaries

Some student bursaries are available from the RSC and SCI, up to a maximum value of £250.
The closing date for all bursary applications is Monday 31 March, and those submitting abstracts will be considered more favourably.